On January 25, 2017, Meridian revealed its negative first-quarter 2017 fiscal year ("1Q 2017") financial results, amended its formerly issued revenue forecast for the 2017 fiscal year downwards, and stated that the Board of Directors reduced the annual indicated dividend rate. John A. Kraeutler, Chief Executive Officer, ascribed the negative quarterly results to revenue declines in Meridian's Americas diagnostic business, Meridian's largest profit driver, across all major product categories, "due to customer buying patterns and general weakness overall." Following this news, Meridian stock dropped during intraday trading on January 25, 2017.
If you are aware of any facts relating to this investigation, or purchased Meridian shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/vivo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-meridian-bioscience-inc-vivo-300396969.html
SOURCE Bronstein, Gewirtz & Grossman, LLC